Aviado · Research
Longevity Daily
Thursday, June 18, 2026
Listen
Today's Brief
Today's strongest stories share a throughline: the longevity field is moving decisively from observation to intervention. The must-read comes from Neurology — a large multi-cohort study showing that "super movers" aged 80 and older carry a 51% lower risk of dementia, with preserved hippocampal volume and slower cognitive decline to match. Also in this edition, Axios reports on the world's first human trial testing whether a drug can make cells biologically younger — a genuine milestone for the field. And long-term DPP data delivers a useful reminder that lifestyle changes still outperform metformin when it comes to preventing multimorbidity.
10 stories4 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
Fast Walkers Over 80 Cut Dementia Risk in Half — A Large Multi-Cohort Study Explains Why
People aged 80 and older who walk faster than their peers — dubbed 'super movers' — are 51% less likely to develop cognitive impairment than slower walkers, according to a multi-cohort meta-analysis in Neurology drawing on nearly 4,000 adults. Super movers also showed slower memory and non-memory decline, better preserved hippocampal volume in key subfields, and lower Alzheimer's rates at autopsy — suggesting gait speed is tracking genuine neural resilience, not just baseline health. The brain structural differences held even after adjusting for age, sex, education, and parental longevity. If you're not already measuring your walking speed, this study — one of the largest of its kind — is a compelling reason to start.
Read more →Can Rapamycin Reverse Alzheimer's? A Leading Researcher Breaks Down a Decade of mTOR Data
Dr. Veronica Galvan, director of the Nathan Shock Center and editor-in-chief of Geroscience, reviews more than ten years of research on rapamycin, mTOR signaling, and brain aging — and the picture is more complicated than the hype suggests. Animal data has been encouraging, but Galvan cautions that dose, timing, and individual biological variation all create serious obstacles to human translation. If you've been following the rapamycin-for-dementia conversation, this is the most substantive look at what the evidence actually does and doesn't support.
Read more →Supplements & Compounds
Blackcurrant Extract Improves Brain Focus and Muscle Power in Double-Blind Crossover Trial
A randomized, double-blind, placebo-controlled crossover study on New Zealand blackcurrant extract found dose-dependent improvements in both cognitive focus and physical power output after short-term supplementation. The dual cognitive-and-performance signal is notable — most supplement trials optimize for one outcome or the other. Longer trials in older adults are still needed to confirm whether these effects persist, but the study design is methodologically solid.
Read more →Creatine Is No Longer Just for Athletes — Here's What the Aging and Brain Research Shows
Once confined to sports nutrition, creatine is gaining serious traction as a longevity compound, with emerging research spotlighting its role in ATP recycling, mitochondrial health, and neuroenergetics. High-dose creatine monohydrate (15–20g) or lower-dose creatine HCl (~0.75–1.5g) may meaningfully raise brain creatine levels, potentially improving cognitive resilience under stress and with aging. The piece also examines new formulations designed for older adults who find standard powders hard to tolerate.
Read more →Research & Papers
Longevity Medicine's Most Important Test: The World's First Human Trial of Cellular Age Reversal Has Launched
Axios reports on what may be the longevity field's defining moment: the launch of the first early-stage human clinical trial designed to test whether a drug can make cells biologically younger. The trial will provide the first human reality check for partial cellular reprogramming, arguably the most theoretically promising — and most hyped — approach in aging research. Success or failure at this phase will shape research priorities and investment across the entire field for years to come.
Read more →Late-Life Gene Therapy Boosts Mouse Lifespan by 20% and Improves Multiple Healthspan Markers
A new mouse study found that muscle-targeted viral-vector delivery of the protein FGF21 increased median lifespan in male mice by approximately 20%, even when the intervention began late in life. Treated mice also showed improvements across multiple healthspan markers, suggesting FGF21 acts on metabolic regulation broadly rather than through a single pathway. This is a mouse study and the path to human translation remains long — but the late-life intervention window is precisely what makes the finding translationally interesting.
Read more →Biological Age Clocks Are Getting Sharper — and May Soon Predict Disease Before Symptoms Appear
A review in the Journal of Clinical Investigation traces the evolution of biological age measurement — from functional tests and blood biomarkers to epigenetic, proteomic, wearable, and AI-based clocks — and finds these tools already outperform chronological age for predicting health risk. The authors call for standardization of methods and larger validation cohorts before clinical deployment. For health optimizers already using epigenetic clocks, this review validates the general approach while flagging meaningful limitations in the current generation of tools.
Read more →Aviado Research Review: Evaluating the Evidence on Longevity Interventions
This Aviado Research analysis surveys the current evidence landscape across longevity interventions, synthesizing recent findings in cellular biology, supplementation, and lifestyle medicine. The goal: help readers separate robust, actionable signals from premature hype in a fast-moving field.
Read the full Aviado analysis →Lifestyle & Nutrition
Diet, Weight Loss, and 150 Minutes of Weekly Exercise Cut Multimorbidity Risk by 21% — Beating Metformin
A long-term analysis of 1,173 adults from the Diabetes Prevention Program Outcomes Study found that combining dietary changes, modest weight loss, and 150 weekly minutes of moderate exercise reduced the risk of developing multiple chronic diseases by 21% — outperforming both metformin and placebo over years of follow-up. The lifestyle group's advantage persisted across the full follow-up period, reinforcing that metabolic resilience is primarily built through behavior. For those using metformin as a longevity intervention, this is a useful data point: the drug is not a substitute for the fundamentals.
Read more →Industry & Policy
Supplement Companies Sue FDA Over Blocked Disease-Prevention Claims
A nonprofit advocacy group and several supplement manufacturers have filed a federal lawsuit challenging the FDA's longstanding refusal to allow dietary supplements to make disease-risk reduction claims, even when those claims are grounded in statements from government health agencies. The case tests a legal tension that has shaped supplement marketing and consumer information for decades. Its outcome could significantly expand — or permanently restrict — what companies are permitted to communicate on product labels.
Read more →